# The Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC)

> **NIH NIH U19** · UNIVERSITY OF ARIZONA · 2020 · $561,279

## Abstract

PROJECT SUMMARY
The Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2)-driven coronavirus disease 2019
(COVID-19) pandemic has fundamentally changed our world, country, community and families. In patients who
die of COVID-19, activation of evolutionarily-conserved inflammatory cascades results in massive increases in
circulating levels of inflammatory cytokines producing vascular leak, edema of multiple critical organ (lung,
kidneys, heart, brain, liver, GI tract), ultimately leading to multi-organ dysfunction including acute respiratory
distress syndrome (ARDS). There is lack of deep understanding regarding the risk factors for and biology of
COVID-19. The pandemic has also dramatically highlighted the multiple unmet needs in the care for patients
with SARS-CoV-2 infection including the lack of validated biomarkers, and of effective FDA–approved
pharmacotherapies. Accordingly, this Administrative Supplement seeks to further our understanding through
immunophenotyping patients who develop COVID-19. We will provide clinical data and sample
collection/processing from a cohort of SARS-CoV2 patients enrolled in Tucson, Arizona. The clinical data and
samples will be transmitted to the central cores that are assigned by the Immunophenotyping Assessment in a
COVID-19 Cohort (IMPACC) study with the overarching objectives to better understand the pathogenesis
of COVID-19 disease and to identify immunological pathways that can be used to inform us on how to
combat this disease. In Specific Aim 1, we will recruit and provide clinical data (demographics, clinical
laboratory test results and imaging results, clinical course) longitudinally from patients hospitalized with COVID-
19 infection to the designated IMPACC cores in order to establish correlation with immune status and disease
progression. In Specific Aim 2, we will provide biological specimens (serum, whole blood, PBMCs,
nasopharyngeal samples, endotracheal aspirates) from patients hospitalized with COVID-19 infection to the
designated cores in order to characterize the immunophenotypes and the immune status and response to
infection. This supplement supports the University of Arizona's participation in IMPACC to facilitate screening
and enrollment of inpatients with COVID-19. The proposed supplement research is within the scope of parent
U19 grant entitled “Dysfunction of Innate Immunity in Asthma” (1U19AI125357). In summary, the IMPACC study
coordinates a national, multi-institution consortium, collecting detailed clinical data and biologic samples from
hospitalized COVID-19 infected individuals, with the goal of identifying immune signatures/molecular biomarkers
associated with clinical disease course. These data will allow the prioritization of clinical interventions and
therapeutic decision making.

## Key facts

- **NIH application ID:** 10204632
- **Project number:** 3U19AI125357-05S1
- **Recipient organization:** UNIVERSITY OF ARIZONA
- **Principal Investigator:** Monica Kraft
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $561,279
- **Award type:** 3
- **Project period:** 2020-07-21 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10204632

## Citation

> US National Institutes of Health, RePORTER application 10204632, The Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) (3U19AI125357-05S1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10204632. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*